百克生物 - Financials

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	1.2B	1.8B	1.1B	1.2B	1.4B
Revenue Growth %	-32.7%	70.4%	-10.9%	-16.6%	--
Total Revenue	1.2B	1.8B	1.1B	1.2B	1.4B
Cost Of Revenue	179.0M	178.0M	137.0M	141.0M	168.0M
+Gross Profit	1.1B	1.6B	934.0M	1.1B	1.3B
Gross Margin %	85.4%	90.2%	87.2%	88.3%	88.3%
Total Operating Cost	976.0M	1.3B	891.0M	951.0M	973.0M
Selling Expenses	475.0M	647.0M	412.0M	453.0M	578.0M
Admin Expenses	113.0M	159.0M	144.0M	108.0M	119.0M
Rd Expenses	156.0M	198.0M	134.0M	157.0M	93.4M
Finance Expenses	-3.8M	-12.2M	-20.1M	-11.1M	3.5M
+Operating Income	258.0M	559.0M	187.0M	262.0M	482.0M
Operating Margin %	21.0%	30.6%	17.5%	21.8%	33.4%
Non Operating Income	4.9M	8.5M	12.1M	2.5M	5.8M
Non Operating Expenses	7.0M	4.0M	1.3M	2.8M	1.3M
Investment Income	-440,300	690,000	308,100	-1.0M	6.4M
Asset Disposal Income	2,800	20,800	--	77.00	--
Asset Impairment Loss	40.0M	55.2M	62.4M	87.7M	--
Other Income	4.8M	4.4M	6.6M	12.3M	7.1M
Income Before Tax	256.0M	564.0M	198.0M	262.0M	487.0M
Income Tax	23.7M	62.7M	16.2M	18.0M	68.4M
+Net Income	232.0M	501.0M	182.0M	244.0M	418.0M
Net Margin %	18.9%	27.5%	17.0%	20.3%	29.0%
Net Income Attributable	232.0M	501.0M	182.0M	244.0M	418.0M
Eps Basic	0.56	1.21	0.44	0.62	1.14
Eps Diluted	0.56	1.21	0.44	0.62	1.14

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	345.0M	442.0M	867.0M	1.2B	310.0M
Accounts Receivable	1.4B	1.6B	968.0M	764.0M	733.0M
Notes Receivable	1.0M	3.6M	--	--	--
Notes And Accounts Receivable	1.4B	1.6B	968.0M	764.0M	733.0M
Prepayments	25.1M	31.0M	27.3M	18.1M	11.5M
Inventory	171.0M	199.0M	192.0M	241.0M	146.0M
Total Current Assets	2.0B	2.2B	2.1B	2.2B	1.2B
Long Term Equity Investment	33.5M	34.9M	34.2M	35.9M	4.3M
Fixed Assets	--	984.0M	604.0M	519.0M	548.0M
Fixed Assets Total	1.1B	984.0M	604.0M	519.0M	548.0M
Construction In Progress	--	1.1B	1.0B	920.0M	235.0M
Construction In Progress Total	1.4B	1.1B	1.0B	920.0M	235.0M
Intangible Assets	331.0M	347.0M	204.0M	224.0M	249.0M
Long Term Deferred Expenses	74.7M	29.3M	32.6M	3.0M	1.3M
Total Non Current Assets	3.2B	2.8B	2.2B	2.0B	1.2B
Total Assets	5.2B	5.0B	4.3B	4.2B	2.5B
Short Term Borrowings	42.9M	20.5M	--	--	--
Accounts Payable	13.7M	17.5M	24.8M	63.9M	34.0M
Advance Receipts	--	--	--	--	--
Contract Liabilities	2.2M	283,100	8.6M	10.2M	6.2M
Total Current Liabilities	917.0M	1.0B	717.0M	749.0M	680.0M
Long Term Borrowings	59.9M	--	--	--	--
Total Non Current Liabilities	70.1M	11.0M	7.3M	8.3M	7.9M
Total Liabilities	987.0M	1.0B	724.0M	757.0M	688.0M
Paid In Capital	414.0M	413.0M	413.0M	413.0M	372.0M
Capital Reserve	1.8B	1.8B	1.8B	1.8B	416.0M
Surplus Reserve	534.0M	486.0M	378.0M	334.0M	283.0M
Retained Earnings	1.5B	1.3B	1.0B	906.0M	740.0M
Equity Attributable	4.2B	4.0B	3.6B	3.4B	1.8B
Total Equity	4.2B	4.0B	3.6B	3.4B	1.8B

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	1.4B	1.2B	933.0M	1.2B	1.1B
Total Operating Cash Inflow	1.5B	1.4B	1.0B	1.3B	1.2B
Cash Paid For Goods	90.7M	128.0M	127.0M	197.0M	146.0M
Cash Paid To Employees	214.0M	178.0M	187.0M	203.0M	132.0M
Taxes Paid	140.0M	121.0M	77.9M	103.0M	122.0M
Total Operating Cash Outflow	1.1B	1.1B	998.0M	1.2B	962.0M
Operating Cash Flow	407.0M	255.0M	39.8M	140.0M	209.0M
Total Investing Cash Inflow	941,300	36,000	2.0M	3.4M	322.0M
Total Investing Cash Outflow	542.0M	639.0M	291.0M	699.0M	656.0M
Investing Cash Flow	-541.0M	-639.0M	-289.0M	-696.0M	-334.0M
Cash From Borrowings	337.0M	197.0M	--	67.5M	69.9M
Dividends And Interest Paid	64.4M	62.6M	41.3M	328,800	4.0M
Debt Repayments	254.0M	176.0M	0.00	67.5M	235.0M
Total Financing Cash Inflow	356.0M	197.0M	--	1.5B	420.0M
Total Financing Cash Outflow	319.0M	239.0M	41.3M	77.9M	246.0M
Financing Cash Flow	37.0M	-42.1M	-41.3M	1.4B	174.0M
Net Change In Cash	-97.3M	-425.0M	-289.0M	847.0M	49.9M
Ending Cash Balance	339.0M	437.0M	862.0M	1.1B	303.0M
Capex	542.0M	471.0M	291.0M	633.0M	336.0M